Verona Pharma plc (VRNA)
Oct 7, 2025 - VRNA was delisted (reason: acquired by MRK)
106.91
+0.12 (0.11%)
Inactive · Last trade price
on Oct 6, 2025
Verona Pharma Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Verona Pharma stock had an average target of 114.1, with a low estimate of 57 and a high estimate of 170.
Analyst Consensus: Buy
* Price targets were last updated on Oct 8, 2025.
Analyst Ratings
The average analyst rating for Verona Pharma stock from 11 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 3 | 3 | 3 | 3 |
| Buy | 1 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 8 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Suspends $100 | Buy | Suspends | $100 | -6.46% | Oct 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $90 → $107 | Strong Buy → Hold | Downgrades | $90 → $107 | +0.08% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $138 → $107 | Buy → Hold | Downgrades | $138 → $107 | +0.08% | Jul 10, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $140 → $107 | Strong Buy → Hold | Downgrades | $140 → $107 | +0.08% | Jul 9, 2025 |
Financial Forecast
Revenue This Year
427.00M
from 42.28M
Increased by 909.96%
Revenue Next Year
753.54M
from 427.00M
Increased by 76.47%
EPS This Year
0.52
from -2.16
EPS Next Year
2.20
from 0.52
Increased by 325.94%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 514.5M | 943.3M | |||
| Avg | 427.0M | 753.5M | |||
| Low | 361.7M | 545.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,116.9% | 120.9% | |||
| Avg | 910.0% | 76.5% | |||
| Low | 755.5% | 27.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.56 | 4.46 | |||
| Avg | 0.52 | 2.20 | |||
| Low | -0.11 | 0.37 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 762.1% | |||
| Avg | - | 325.9% | |||
| Low | - | -28.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.